The role of FGF binding protein HBp17 in cancer stem cells of oral cancer and application for the molecular target therapy.
Project/Area Number |
22791982
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Surgical dentistry
|
Research Institution | Hiroshima University |
Principal Investigator |
|
Project Period (FY) |
2010 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 増殖因子 / ビタミンD3 / 癌幹細胞 / 分子標的治療 / FGF結合蛋白 |
Research Abstract |
By assuming the expression of HBp17 in an oral cancer cell line, we treated them with 1α, 25(OH)_2D_3(VD_3). We investigated the expression of HBp17, FGF-2 and NF-κB molecules. Reporter assays were done for proof of down-regulation of these molecules. The HBp17 expression was down-regulated with VD3. There are no changes in NF-κB expression(p65 or p50). However the expression of IκB-α was increased and its phosphorylation was decreased. Investigation on the HBp17 promoter activity by luciferase reporter assays showed the down-regulation of this molecule by VD3. We found that HBp17 expression in nuclear decreased by VD3 treatment with immunofluorescence cytochemistry. We concluded that VD3 down-regulated HBp17 expression by inhibiting DNA binding of NF-κB.
|
Report
(3 results)
Research Products
(3 results)